Clinical Trials

MenoGeniX has completed a multi-site, double-blind, randomized, placebo-controlled Phase 1b clinical trial to evaluate the effectiveness of MNGX-100.

Designed in accordance with FDA guidelines for hormone therapies to treat hot flashes, participants in the study were stratified by naturally-occurring vs. surgically-induced menopause. The results of the study showed a statistically significant reduction in hot flash frequency and severity, and demonstrated the greatest effect in subgroups within the test population that have been reported to have the highest symptom burden from hot flashes.

A Phase II clinical trial with an expanded study population is planned for 2017.